

acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180.

26. (amended) An isolated non-human antibody or fragment thereof which specifically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180.

29. (amended) A monoclonal antibody or fragment thereof which specifically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:3, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180.

36. (amended) A substantially purified antibody or a fragment thereof which specifically binds to an extracellular domain of the amino acid sequence of SEQ ID NO:3.

37. (amended) The antibody of claim 36, wherein the extracellular domain comprises amino acid residues 21 to 269 of SEQ ID NO:3.

39. (amended) The antibody of claim 38, wherein the immunoglobulin-like domain comprises amino acid residues 48 to 88 or 134 to 180 of SEQ ID NO:3.

48. (amended) An antibody Fc region fusion polypeptide comprising an antibody Fc region linked to the amino acid sequence of SEQ ID NO:3, the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180, or a fragment of at least 15 amino acid residues of the amino acid sequence of SEQ ID NO:3.

49. (amended) The antibody Fc region fusion polypeptide of Claim 48, wherein the amino acid sequence comprises an extracellular domain of the amino acid sequence of SEQ ID NO:3.

50. (amended) The antibody of claim 49, wherein the extracellular domain comprises amino acid residues 21 to 269 of SEQ ID NO:3.

52. (amended) The antibody of claim 51, wherein the immunoglobulin-like domain comprises amino acid residues 48 to 88 or 134 to 180 of SEQ ID NO:3.

65. (amended) A method of making an antibody that specifically recognizes GPVI, the method comprising:

- a) immunizing a mammal with a polypeptide comprising the amino acid sequence of SEQ ID NO:3, the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 207180, or a fragment of at least 15 amino acid residues of the amino acid sequence of SEQ ID NO:3; and
- b) collecting a sample from the mammal that contains an antibody that specifically recognizes GPVI.

70. (amended) The method of claim 65 wherein the antibody specifically binds to an extracellular domain of the amino acid sequence of SEQ ID NO:3.

#### REMARKS

Claims 24-70 are pending in this application. The Examiner has required an election under 35 U.S.C. § 121 of one of the following groups:

- I. Claims 24-64, drawn to an antibody that binds specifically to SEQ ID NO:3, ATCC Accession No. 207180, pharmaceutical compositions and kits classified in Class 424, subclass 130.1.
- II. Claims 24-64, drawn to an antibody that binds specifically to SEQ ID NO:16, ATCC No. PTA-225, pharmaceutical compositions and kits, classified in Class 424, subclass 178.1.
- III. Claims 65-70, drawn to a method of making antibody, classified in Class 435, subclass 70.21.